Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, CASI Pharmaceuticals's Enterprise Value is $24.51 Mil.
CASI Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil. Therefore, CASI Pharmaceuticals's EV-to-OCF for today is .
The historical rank and industry rank for CASI Pharmaceuticals's EV-to-OCF or its related term are showing as below:
CASIF'
s EV-to-OCF Range Over the Past 10 Years
Min: -97.07 Med: -7.25 Max: 0.25
Current: -1.18
During the past 13 years, the highest EV-to-OCF of CASI Pharmaceuticals was 0.25. The lowest was -97.07. And the median was -7.25.
CASIF's EV-to-OCF is ranked worse than 62.37% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs CASIF: -1.18
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CASI Pharmaceuticals (OTCPK:CASIF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CASI Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
CASI Pharmaceuticals's share price for today is $0.129.
CASI Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CASI Pharmaceuticals EV-to-OCF Related Terms
CASI Pharmaceuticals EV-to-OCF Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CASI Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's EV-to-OCF falls into.
CASI Pharmaceuticals's current Enterprise Value is $24.51 Mil.
CASI Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.13 is trading 88.3% below its estimated GF Value™ of $1.10.
GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CASIF:
EV-to-OCF:
GF Value™: $1.10 vs. price of $0.13 (88.3% below fair value)
No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for CASIF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASIF has been successfully added to your 
